The U.S. Food and Drug Administration has made changes to the labels for fluoroquinolone antibacterial drugs administered by mouth or injection to address potential serious safety issues. The revised “boxed warning,” the agency’s strongest warning, notes that the drugs are “associated with disabling and potentially permanent side effects of the tendons, muscles, joints, nerves, and central nervous system” that can occur together. “Health care professionals should not prescribe systemic fluoroquinolones to patients who have other treatment options for acute bacterial sinusitis (ABS), acute bacterial exacerbation of chronic bronchitis (ABECB), and uncomplicated urinary tract infections (UTI) because the risks outweigh the benefits in these patients,” the agency states. For more, see the FDA Safety Announcement.

Related News Articles

Headline
The Department of Health and Human Services Sept. 3 announced it will increase resources to curb information blocking and take action against health care…
Headline
The AHA Sept. 3 released a study conducted by KNG Health Consulting that found Medicare patients who receive care in a hospital outpatient department are more…
Headline
The Centers for Medicare & Medicaid Services Innovation Center Sept. 2 announced changes to the Achieving Healthcare Efficiency through Accountable Design…
Headline
Chinese state-sponsored cyber actors are maliciously targeting networks globally, including telecommunications, government and others, according to a joint…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
Randy Fagin, M.D., chief quality officer at HCA Healthcare, shares insights into the organization’s bold approach to improving safety outcomes. From piloting…